Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2002 2
2003 2
2004 2
2005 7
2006 5
2007 7
2008 5
2009 5
2010 7
2011 13
2012 9
2013 19
2014 17
2015 13
2016 17
2017 14
2018 13
2019 14
2020 39
2021 23
2022 36
2023 35
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials.
Wakkerman FC, Wu J, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, Haverkort MAD, de Jong MA, Mens JWM, Wortman BG, Nout RA, Léon-Castillo A, Powell ME, Mileshkin LR, Katsaros D, Alfieri J, Leary A, Singh N, de Boer SM, Nijman HW, Smit VTHBM, Bosse T, Koelzer VH, Creutzberg CL, Horeweg N. Wakkerman FC, et al. Among authors: mileshkin lr. Lancet Oncol. 2024 Apr 30:S1470-2045(24)00142-6. doi: 10.1016/S1470-2045(24)00142-6. Online ahead of print. Lancet Oncol. 2024. PMID: 38701815
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Werner B, Sjoquist KM, Espinoza D, Yip S, Chang G, Cummins MM, Mileshkin L, Ananda S, Shannon C, Friedlander M, Warton K, Ford CE. Werner B, et al. Among authors: mileshkin l. Transl Oncol. 2024 May;43:101914. doi: 10.1016/j.tranon.2024.101914. Epub 2024 Feb 27. Transl Oncol. 2024. PMID: 38417292 Free PMC article.
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
Tjokrowidjaja A, Friedlander ML, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Lord SJ, Scott CL, Goble S, York W, Lee CK; Gynecologic Cancer Intergroup Meta-Analysis Committee. Tjokrowidjaja A, et al. J Clin Oncol. 2024 Apr 10;42(11):1301-1310. doi: 10.1200/JCO.23.01182. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215359
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
Kaya M, Post CCB, Tops CM, Nielsen M, Crosbie EJ, Leary A, Mileshkin LR, Han K, Bessette P, de Boer SM, Jürgenliemk-Schulz IM, Lutgens L, Jobsen JJ, Haverkort MAD, Nout RA, Kroep J, Creutzberg CL, Smit VTHBM, Horeweg N, van Wezel T, Bosse T. Kaya M, et al. Among authors: mileshkin lr. Mod Pathol. 2024 Mar;37(3):100423. doi: 10.1016/j.modpat.2024.100423. Epub 2024 Jan 6. Mod Pathol. 2024. PMID: 38191122 Free article.
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB, Federer-Gsponer J, Pauli C, Karapetyan AR, Chalabi N, Durán-Pacheco G, Beringer A, Bochtler T, Cook N, Höglander E, Jin DX, Losa F, Mileshkin L, Moch H, Ross JS, Sokol ES, Tothill RW, Krämer A. Westphalen CB, et al. Among authors: mileshkin l. ESMO Open. 2023 Dec;8(6):102035. doi: 10.1016/j.esmoop.2023.102035. Epub 2023 Nov 2. ESMO Open. 2023. PMID: 37922692 Free PMC article.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view.
Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A. Le Tourneau C, et al. Among authors: mileshkin l. Eur J Cancer. 2023 Nov;194:113278. doi: 10.1016/j.ejca.2023.113278. Epub 2023 Aug 4. Eur J Cancer. 2023. PMID: 37820553 Free article. Review.
280 results